News Column

New Radiotherapy Findings Reported from O. Neumann and Co-Authors (Robotic radiosurgery as an alternative to brachytherapy for cervical cancer...

June 30, 2014



New Radiotherapy Findings Reported from O. Neumann and Co-Authors (Robotic radiosurgery as an alternative to brachytherapy for cervical cancer patients)

By a News Reporter-Staff News Editor at Robotics & Machine Learning -- Investigators discuss new findings in Drugs and Therapies. According to news reporting out of Berlin, Germany, by VerticalNews editors, research stated, "To compare MRI-guided brachytherapy (BT) and two different dose prescriptions for robotic radiosurgery (RRS) in locally advanced cervical cancer. Eleven patients with FIGO stage IIB-IIIB cervical cancer underwent RRS instead of BT for various reasons."

Our news journalists obtained a quote from the research, "A total dose of 30 Gy was administered in five fractions. The maximum dose was chosen such that the prescribed dose was 70 % of the maximum dose (RRS70). To simulate BT more closely, additional plan calculations were carried out for a higher maximum dose with the same enclosing dose of 30 Gy being now 25 % of the maximum dose (RRS25). BT plans were calculated for the same patients (BTRRS). Finally, the resulting three sets of treatment plans were compared with 38 other patients treated with MRI-guided BT and the same dose prescription (BTref). Plan comparisons were performed based on DVH parameters with regard to target coverage (V100), conformation number (CN), and sparing of the organs at risk (OARs). The best coverage of V100 = 100 +/- 0 % was obtained with RRS25, followed by RRS70 with 97.1 +/- 2.7 %, BTref with 90.9 +/- 8.9 %, and the intraindividual BTRRS with 80.6 +/- 6.4 %. The sparing of OARs was associated with D0.1 cc, D2 cc, and D5 cc to the rectum, sigmoid, and bladder walls. OAR doses were compliant with the GEC-ESTRO guidelines and comparable among RRS70, RRS25, BTRRS, and BTref. By contrast, RRS25 could not fulfill these guidelines, exceeding considerably the tolerable dose constraints for the walls of the critical OARs. Despite of the excellent coverage and higher maximum dose, the unacceptably high exposure to the OARs disqualified RRS25 as an alternative for BT in cervical cancer patients."

According to the news editors, the research concluded: "By contrast, RRS70 offered the best protection for the OARs, comparable to BT, and even better target coverage and conformity than BT."

For more information on this research see: Robotic radiosurgery as an alternative to brachytherapy for cervical cancer patients. Strahlentherapie Und Onkologie, 2014;190(6):538-545. Strahlentherapie Und Onkologie can be contacted at: Urban & Vogel, Neumarkter Strasse 43, D-81673 Munich, Germany. (Springer - www.springer.com; Strahlentherapie Und Onkologie - www.springerlink.com/content/0179-7158/)

Our news journalists report that additional information may be obtained by contacting O. Neumann, Charite CyberKnife Center, Berlin, Germany. Additional authors for this research include A. Kluge, O. Lyubina, W. Wlodarczyk, U. Jahn, C. Kohler, V. Budach, M. Kufeld and S. Marnitz.

Keywords for this news article include: Berlin, Europe, Cancer, Germany, Oncology, Robotics, Radiotherapy, Brachytherapy, Machine Learning, Drugs and Therapies, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Robotics & Machine Learning


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters